Laurent Pharmaceuticals Receives US$ 3M Development Award From Cystic Fibrosis Foundation Therapeutics
First Canadian Company To Obtain CFFT Therapeutics Development Award
MONTREAL, QC, Canada – July 26th, 2016
Laurent Pharmaceuticals Inc. (the “Company”), a clinical stage orphan drug company, today announced it has received a Therapeutics Development Award of up to US$3 million from US-based Cystic Fibrosis Foundation Therapeutics, Inc. (“CFFT”), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation. The award will help support the Phase 2 clinical trial of the Company’s lead drug candidate LAU-7b in adult patients with cystic fibrosis (“CF”).